Valuation
- Market cap
- 1,654,800,000
- Revenue TTM
- $0
- Net income TTM
- $-287,860,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.60
Trading
- Volume
- 2,664,400
- Avg volume
- 2,776,828
- Day's range
- $11.63 – $12.07
- Shares out
- 138,477,000
- Stochastic %K
- 7%
- Beta
- 2.55
- Analysts
- Strong Sell
- Price target
- $23.20
Company profile
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx L...
Show more
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
- Industry
- Medical Care Facilities
- Sector
- Healthcare
- Phone
- 44 716 6766461
- Website
- https://compasspathways.com
- Address
- 33 Broadwick Street, London, United Kingdom
Latest news
No headlines yet.
